A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors

Author: Burris Howard   Jones Suzanne   Williams Daphne   Kathman Steven   Hodge Jeffrey   Pandite Lini   Ho Peter   Boerner Scott   LoRusso Patricia  

Publisher: Springer Publishing Company

ISSN: 0167-6997

Source: Investigational New Drugs, Vol.29, Iss.3, 2011-06, pp. : 467-472

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content